Vaspin (SERPINA12): Visceral Adipose Tissue-Derived Serine Protease Inhibitor and Insulin Sensitizer in Metabolic Research

# Vaspin (SERPINA12): Visceral Adipose Tissue-Derived Serine Protease Inhibitor and Insulin Sensitizer in Metabolic Research

Vaspin is a 45-kDa secreted protein belonging to the serine protease inhibitor (serpin) superfamily, encoded by the SERPINA12 gene and predominantly produced in visceral omental adipose tissue. Its name is an acronym derived from its tissue of origin and function: Visceral adipose tissue-derived serine protease inhibitor. Identified in 2005 as an adipokine with insulin-sensitizing properties in obese, diabetic rat models, vaspin attracted immediate attention as a potential link between visceral adiposity and metabolic dysregulation. Its identification as an endogenous inhibitor of tissue kallikrein 7 (KLK7) in 2013 provided the first clear molecular mechanism of action, connecting vaspin to insulin receptor signaling through protease-mediated degradation pathways.

Discovery and Initial Characterization

Vaspin was identified by Hida et al. (2005, PMID: 16439475) in the laboratory of Yuji Matsuzawa at Osaka University, using a systematic approach to identify adipokines expressed specifically in visceral adipose tissue. The team compared gene expression profiles of omental fat from Otsuka Long-Evans Tokushima Fatty (OLETF) rats — a genetic model of visceral obesity and type 2 diabetes — at different stages of disease progression. They found that SERPINA12 expression was highest in OLETF rats at a specific age (24 weeks, when the rats are obese but not yet severely diabetic) and decreased as diabetes worsened, suggesting a compensatory adaptive response.

Key findings from the initial characterization:

1. Vaspin was expressed preferentially in visceral (omental) fat compared to subcutaneous fat in both rats and humans

2. Recombinant vaspin administration (ICV or subcutaneous) to ob/ob mice and HFD mice improved glucose tolerance and insulin sensitivity

3. Vaspin treatment of 3T3-L1 adipocytes enhanced insulin-stimulated glucose uptake and suppressed expression of diabetes-associated genes (resistin, TNF-α)

4. Human plasma vaspin was higher in obese subjects than lean controls (a surprising early finding that was later nuanced by subsequent studies)

Gene Structure and Protein Biology

SERPINA12 Gene

The human SERPINA12 gene is located on chromosome 14q32.1, within the serpin gene cluster that also contains SERPINA1 (α1-antitrypsin), SERPINA3 (α1-antichymotrypsin), and other serine protease inhibitors. The gene encodes a 415-amino acid protein with a signal peptide (residues 1-22) and a 393-amino acid mature form (~45 kDa). The protein is N-glycosylated, and the native circulating form runs at approximately 47-50 kDa on reducing SDS-PAGE.

Serpin Mechanism and Reactive Center Loop

Vaspin belongs to the clade A serpins and uses the canonical serpin "suicide inhibitor" mechanism:

1. The reactive center loop (RCL) of vaspin (approximately residues 375-399) is positioned as a pseudosubstrate, mimicking a protease cleavage site

2. The target serine protease binds the RCL and begins the catalytic cleavage reaction

3. After the initial acyl-enzyme intermediate forms (covalent bond between protease active site Ser and the P1 carbonyl carbon of vaspin), vaspin undergoes a dramatic conformational change

4. The cleaved RCL translocates from one pole of the molecule to the opposite pole, dragging the covalently attached protease with it and distorting the protease active site

5. The result is an extremely stable, covalently linked vaspin-protease complex where the protease is irreversibly inactivated

This 1:1 stoichiometric inhibition is irreversible under physiological conditions. The P1 residue of the vaspin RCL (Leu381) determines its serine protease target selectivity — leucine at P1 is compatible with chymotryptic (chymotrypsin-like, Phe/Tyr/Leu-selective) serine proteases but not tryptic (Arg/Lys-selective) proteases.

Kallikrein 7 (KLK7) as the Primary Target

KLK7 is a chymotryptic serine protease expressed in skin, adipose tissue, and other tissues, with known roles in:

• •Skin barrier desquamation (cleaves corneodesmosin and desmoglein 1)
• •Processing of inflammatory mediators
• •Cleavage and inactivation of insulin receptor substrate (IRS) proteins

The KLK7-IRS connection is mechanistically important: KLK7 cleaves IRS-1 at multiple sites, reducing its abundance and impairing insulin signal transduction. By inhibiting KLK7, vaspin prevents IRS-1 degradation, preserving insulin receptor → IRS-1 → PI3K → Akt signal transmission. This mechanism explains how vaspin sensitizes insulin action without directly activating the insulin receptor.

Additional serine proteases inhibited by vaspin with lower efficiency include kallikrein-related peptidases 1 and 14 (KLK1, KLK14), chymase (from mast cells), and to a lesser extent, some neutrophil-derived serine proteases. The physiological relevance of inhibiting these additional targets beyond KLK7 is less well-characterized.

Cell Surface Receptor: GRP78/BiP

The GRP78 interaction has been reported in adipocytes and neuronal cells, where vaspin through cell surface GRP78 activates Akt and promotes cell survival (anti-apoptotic effect). Whether GRP78 is a true signaling receptor for vaspin or an artifact of in vitro conditions remains somewhat controversial, as cell surface GRP78 expression varies widely with stress conditions. The KLK7 inhibition mechanism is more broadly accepted as the primary mode of action.

Tissue Distribution and Regulation

Expression Pattern

Vaspin/SERPINA12 shows a restricted tissue distribution compared to many adipokines:

• •Adipose tissue: Highest expression in visceral (omental) fat, lower in subcutaneous fat; SVF and mature adipocyte compartments both contribute
• •Hypothalamus: Vaspin is expressed in hypothalamic neurons, particularly in the arcuate nucleus (ARC) and paraventricular nucleus (PVN) — an unusual feature that positions it for central nervous system actions
• •Stomach: Gastric epithelium expresses SERPINA12; vaspin in gastric tissue may modulate mucosal serine protease activity
• •Liver: Low hepatic expression
• •Skin and sweat glands: Consistent with KLK7's known role in skin desquamation

Regulatory Factors

Vaspin expression and secretion are regulated by nutritional status and endocrine signals:

• •Insulin: Insulin treatment increases SERPINA12 expression in adipocytes, creating positive feedback
• •Glucocorticoids: Dexamethasone suppresses vaspin in adipocytes
• •High glucose: Hyperglycemia reduces vaspin expression in vitro
• •TNF-α and IL-6: Pro-inflammatory cytokines suppress SERPINA12 in adipocytes
• •PPARγ agonism: Thiazolidinediones (rosiglitazone) modestly increase vaspin in some systems
• •Exercise: Acute aerobic exercise transiently increases plasma vaspin in some studies

Plasma Vaspin: Clinical Associations

The pattern of plasma vaspin in human metabolic disease is complex and has shown inconsistencies across studies, reflecting genuine biological complexity rather than measurement error:

Obesity and Body Composition

Contrasting with most adipokines that increase with adiposity, vaspin shows a non-linear relationship with obesity:

• •Some studies find elevated vaspin in obese vs. lean subjects (consistent with the initial OLETF rat observations)
• •Other studies find reduced vaspin in morbid obesity and type 2 diabetes
• •The most internally consistent interpretation: vaspin is initially elevated as a compensatory adaptive response to early obesity/insulin resistance, but declines in established T2DM as the adipose tissue becomes chronically inflamed and dysfunctional

This biphasic pattern — elevated in early metabolic dysfunction, reduced in late-stage disease — is biologically plausible: the initial increase reflects the adaptive upregulation of vaspin in response to increasing KLK7 activity and IRS-1 degradation, while the eventual decline reflects β-cell exhaustion, chronic inflammation, and general adipokine dysregulation.

Type 2 Diabetes and Insulin Resistance

• •Plasma vaspin inversely correlates with HbA1c and fasting glucose in cross-sectional studies
• •Lower vaspin quartiles associate with higher HOMA-IR
• •T2DM patients show lower vaspin than age-BMI-matched normoglycemic controls in most studies
• •Vaspin treatment of diabetic mice restores insulin sensitivity, supporting a causal role

Metabolic Syndrome Components

• •Inversely correlates with waist circumference in some populations
• •Inversely associated with systolic blood pressure
• •No consistent relationship with HDL cholesterol across studies

Special Populations

• •PCOS: Plasma vaspin shows mixed results, with some studies finding elevated vaspin in PCOS and others finding no difference
• •Thyroid disease: Elevated in hypothyroidism, reduced in hyperthyroidism
• •Pregnancy: Reduced in gestational diabetes; some studies find reduced in preeclampsia
• •Rheumatoid arthritis: Elevated in RA patients, possibly reflecting a compensatory response to inflammation

Central Nervous System Functions

The hypothalamic expression of vaspin has motivated investigation of central nervous system effects:

Hypothalamic injection: ICV vaspin administration in rodents produces anorexigenic effects (reduced food intake) and improves leptin sensitivity, suggesting vaspin may act in hypothalamic circuits regulating energy balance. This effect does not require peripheral insulin sensitivity changes and appears to involve direct hypothalamic actions.

Leptin resistance reversal: Vaspin treatment partially restored leptin-induced STAT3 phosphorylation in the hypothalamus of diet-induced obese mice, suggesting vaspin can overcome obesity-associated leptin resistance by mechanisms that may involve reduction of IRS-1 degradation in hypothalamic neurons.

Neuronal survival: In neuronal cell lines, vaspin through GRP78/Akt promotes survival against ER stress and oxidative stress-induced apoptosis, potentially relevant to diabetic neuropathy.

Skin Biology

Given KLK7's established role in skin barrier desquamation (KLK7 knockout mice develop ichthyosis-like skin disease; KLK7 overexpression causes psoriasis-like inflammation), vaspin as an endogenous KLK7 inhibitor has relevant dermatological biology:

• •Vaspin is expressed in keratinocytes and sweat gland epithelium
• •Vaspin modulates skin barrier function by controlling the rate of corneodesmosome degradation
• •Plasma vaspin is elevated in psoriasis patients (possibly as a counter-regulatory response to KLK7 overactivity)
• •Topical vaspin application in rodent inflammatory skin models reduces KLK7-mediated barrier disruption

This skin biology connects vaspin to the growing field of skin microbiome-barrier-immunity interactions, where serine protease activity is a key regulatory point.

Research Tools and Experimental Systems

Current Research Frontiers

KLK7 as a drug target in metabolic disease: If KLK7-mediated IRS-1 degradation is a significant driver of insulin resistance, then KLK7 inhibitors — possibly including vaspin-derived peptides or small molecules — could represent a novel class of insulin sensitizers. Unlike current insulin sensitizers (metformin, TZDs, GLP-1 RAs), this would target a protease pathway rather than receptor agonism or enzyme inhibition.

Vaspin in skin inflammatory disease: KLK7 inhibition as a therapeutic strategy for inflammatory skin conditions (atopic dermatitis, psoriasis, Netherton syndrome) is being explored. Vaspin-inspired KLK7 inhibitors with improved skin penetration and stability could complement biologic treatments.

Central vaspin-leptin axis: The hypothesis that central vaspin treatment can overcome leptin resistance has therapeutic implications for obesity, since leptin resistance (rather than leptin deficiency) is the major barrier to leptin-based obesity treatment. Intranasal vaspin delivery that bypasses the blood-brain barrier could potentially restore central leptin sensitivity.

Non-enzymatic vaspin signaling: The GRP78 receptor interaction and its downstream signaling require more definitive in vivo validation. If confirmed, cell surface GRP78 represents a second signaling pathway for vaspin with distinct pharmacological implications.

Adipose tissue heterogeneity and vaspin: The preferential visceral vs. subcutaneous vaspin expression is being studied in the context of omental fat depot heterogeneity. Whether specific adipose tissue niches or progenitor populations drive vaspin production may explain the complex clinical associations observed.

Conclusion

Vaspin represents an unusual adipokine — a serine protease inhibitor repurposed by visceral adipose tissue as a paracrine and endocrine regulator of insulin sensitivity. Its mechanistic clarity (serpin inhibition of KLK7 → preserved IRS-1 → enhanced insulin signaling) distinguishes it from many adipokines whose receptors or mechanisms remain unknown. The identification of KLK7 as the primary target positions vaspin in the intersection of adipose biology, skin biology, and insulin resistance — connecting apparently disparate fields through shared serine protease biology. The complex plasma vaspin pattern in obesity (potentially compensatory early, deficient late) suggests it functions as part of an adaptive metabolic response that ultimately fails in chronic obesity and T2DM. Recombinant vaspin, KLK7 activity assays, and the vaspin-KLK7 crystal structure provide well-validated research tools for mechanistic investigation; the OLETF rat and HFD mouse models with ICV/SC vaspin administration are the primary in vivo pharmacology systems. Translation toward therapeutic KLK7 inhibition for metabolic or skin disease represents an underexplored but mechanistically well-founded opportunity.

Key References

4. Klöting N, Berndt J, Kralisch S, et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun. 2006;339(1):430-436. PMID: 16300730

5. Youn BS, Klöting N, Kratzsch J, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes. 2008;57(2):372-377. PMID: 17977954

9. Koiou E, Tziomalos K, Katsikis I, et al. Vaspin in polycystic ovary syndrome. J Clin Endocrinol Metab. 2011;96(2):E299-303. PMID: 21106823

---

This article is intended for Research Use Only (RUO). The information provided describes laboratory research findings and does not constitute medical advice. Vaspin and related serine protease inhibitors are research tools and investigational agents. All research applications must comply with applicable institutional, local, and national regulations.